Calculate CHA₂DS₂-VASc score for stroke risk in atrial fibrillation. Guides anticoagulation decisions with annual stroke risk estimates.
The CHA₂DS₂-VASc Score Calculator estimates annual stroke risk in patients with non-valvular atrial fibrillation (AF) and guides anticoagulation therapy decisions. This scoring system extends the original CHADS₂ score by incorporating additional risk factors — vascular disease, age 65-74, and female sex — to better stratify patients at the lower end of the risk spectrum.
Developed by Gregory Lip and colleagues in 2010, the CHA₂DS₂-VASc score is now recommended by major cardiology guidelines (ESC, AHA/ACC) as the preferred tool for stroke risk assessment in AF. Scores range from 0 to 9, with each point increase associated with incrementally higher annual stroke risk, from 0.2% at score 0 to over 12% at score 9.
Atrial fibrillation affects 2-3% of the population and increases stroke risk 5-fold. Appropriate anticoagulation reduces stroke risk by 60-70%, making accurate risk stratification critical for the estimated 33 million AF patients worldwide. Check the example with realistic values before reporting.
The CHA₂DS₂-VASc score identifies truly low-risk AF patients (score 0 in males, 0-1 in females) who may not need anticoagulation, while ensuring higher-risk patients receive appropriate stroke prevention. This avoids both undertreatment (stroke) and overtreatment (bleeding complications).
Compared to the older CHADS₂ score, CHA₂DS₂-VASc better discriminates patients with intermediate risk scores (CHADS₂ 0-1) who represent a large proportion of clinical decision-making uncertainty.
CHA₂DS₂-VASc = C (CHF, 1) + H (HTN, 1) + A₂ (Age ≥75, 2) + D (DM, 1) + S₂ (Stroke/TIA, 2) + V (Vascular, 1) + A (Age 65-74, 1) + Sc (Sex female, 1) Range: 0-9 for females, 0-8 for males Remember: Age ≥75 gets 2 points (not 1). Prior stroke/TIA gets 2 points.
Result: Score 3 — 3.2% annual stroke risk
Hypertension (+1) + Age 65-74 (+1) + Diabetes (+1) + Male sex (0) = CHA₂DS₂-VASc 3. Annual stroke risk ~3.2%. Anticoagulation is recommended per guidelines.
ESC 2020 guidelines recommend: Score 0 (males) or 1 (females, sex factor only) — no antithrombotic therapy. Score 1 (males) — OAC should be considered. Score ≥2 — OAC is recommended. The AHA/ACC guidelines are similar, with slightly different phrasing about the score 1 category.
Four DOACs are approved for AF stroke prevention: apixaban (ARISTOTLE), rivaroxaban (ROCKET AF), edoxaban (ENGAGE AF), and dabigatran (RE-LY). Meta-analyses show DOACs reduce stroke/systemic embolism by 19% and intracranial hemorrhage by 52% compared to warfarin. Apixaban showed the best safety profile in trials.
Recent research examines whether patients with very low CHA₂DS₂-VASc scores detected by wearable ECG monitoring benefit from anticoagulation. The relationship between AF burden (time in AF vs total monitoring time) and stroke risk is under active investigation, potentially refining treatment decisions beyond simple yes/no anticoagulation.
No. Female sex alone (score 1 in an otherwise zero patient) is considered "low risk" per guidelines. The sex factor is only relevant when other risk factors are present. ESC guidelines recommend viewing female sex as a "risk modifier" rather than an independent risk factor.
DOACs (apixaban, rivaroxaban, edoxaban, dabigatran) are preferred over warfarin for most patients with non-valvular AF based on superior efficacy, safety profile, and convenience. Warfarin remains first-line for mechanical heart valves and moderate-to-severe mitral stenosis.
Yes. Risk factors accumulate with age and comorbidities. A patient who is low-risk at age 50 may become high-risk by age 65-75. Annual reassessment is recommended, especially around age thresholds.
Yes. Stroke risk and anticoagulation recommendations are the same regardless of AF pattern (paroxysmal, persistent, or permanent). All AF types carry similar long-term stroke risk.
HAS-BLED estimates bleeding risk on anticoagulation. Both scores should be calculated together. A high HAS-BLED score does not necessarily contraindicate anticoagulation but identifies modifiable bleeding risk factors and indicates closer monitoring.
LAA closure devices (Watchman) are an alternative for patients with high stroke risk who cannot tolerate long-term anticoagulation. They are not first-line therapy and require careful patient selection.